Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag

Danilo R. Casimiro, Fubao Wang, William A. Schleif, Xiaoping Liang, Zhi Qiang Zhang, Timothy W. Tobery, Mary Ellen Davies, Adrian B. McDermott, David H. O'Connor, Arthur Fridman, Ansu Bagchi, Lynda G. Tussey, Andrew J. Bett, Adam C. Finnefrock, Tong Ming Fu, Aimin Tang, Keith A. Wilson, Minchun Chen, Helen C. Perry, Gwendolyn J. Heidecker & 11 others Daniel C. Freed, Anthony Carella, Kara S. Punt, Kara J. Sykes, Lingyi Huang, Virginia I. Ausensi, Margaret Bachinsky, Usha Sadasivan-Nair, David Watkins, Emilio A. Emini, John W. Shiver

Research output: Contribution to journalArticle

195 Citations (Scopus)

Abstract

The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SFVmac239 challenge. Cohorts of either Mamu-A*01(+) or Mamu-A*01(-) macaques were immunized with a DNA prime-Ad5 boost regimen; for comparison, a third cohort consisting of Mamu-A*01(+) monkeys was immunized using the Ad5 vector alone for both prime and boost. All animals, along with unvaccinated control cohorts of Mamu-A*01(+) and Mamu-A*01(-) macaques, were challenged intrarectally with SFVmac239. Viral loads were measured in both peripheral and lymphoid compartments. Only the DNA prime-Ad5-boosted Mamu-A*01(+) cohort exhibited a notable reduction in peak plasma viral load (sevenfold) as well as in early set-point viral burdens in both plasma and lymphoid tissues (10-fold) relative to those observed in the control monkeys sharing the same Mamu-A*01 allele. The degree of control in each animal correlated with the levels of Gag-specific immunity before virus challenge. However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed.

Original languageEnglish
Pages (from-to)15547-15555
Number of pages9
JournalJournal of Virology
Volume79
Issue number24
DOIs
StatePublished - Dec 1 2005
Externally publishedYes

Fingerprint

Simian immunodeficiency virus
Simian Immunodeficiency Virus
DNA Vaccines
Adenoviridae
recombinant vaccines
Virus Diseases
Immunization
immunization
serotypes
viral load
Viral Load
Macaca
DNA
infection
Haplorhini
monkeys
Vaccines
Viruses
vector vaccines
viruses

ASJC Scopus subject areas

  • Immunology

Cite this

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. / Casimiro, Danilo R.; Wang, Fubao; Schleif, William A.; Liang, Xiaoping; Zhang, Zhi Qiang; Tobery, Timothy W.; Davies, Mary Ellen; McDermott, Adrian B.; O'Connor, David H.; Fridman, Arthur; Bagchi, Ansu; Tussey, Lynda G.; Bett, Andrew J.; Finnefrock, Adam C.; Fu, Tong Ming; Tang, Aimin; Wilson, Keith A.; Chen, Minchun; Perry, Helen C.; Heidecker, Gwendolyn J.; Freed, Daniel C.; Carella, Anthony; Punt, Kara S.; Sykes, Kara J.; Huang, Lingyi; Ausensi, Virginia I.; Bachinsky, Margaret; Sadasivan-Nair, Usha; Watkins, David; Emini, Emilio A.; Shiver, John W.

In: Journal of Virology, Vol. 79, No. 24, 01.12.2005, p. 15547-15555.

Research output: Contribution to journalArticle

Casimiro, DR, Wang, F, Schleif, WA, Liang, X, Zhang, ZQ, Tobery, TW, Davies, ME, McDermott, AB, O'Connor, DH, Fridman, A, Bagchi, A, Tussey, LG, Bett, AJ, Finnefrock, AC, Fu, TM, Tang, A, Wilson, KA, Chen, M, Perry, HC, Heidecker, GJ, Freed, DC, Carella, A, Punt, KS, Sykes, KJ, Huang, L, Ausensi, VI, Bachinsky, M, Sadasivan-Nair, U, Watkins, D, Emini, EA & Shiver, JW 2005, 'Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag', Journal of Virology, vol. 79, no. 24, pp. 15547-15555. https://doi.org/10.1128/JVI.79.24.15547-15555.2005
Casimiro, Danilo R. ; Wang, Fubao ; Schleif, William A. ; Liang, Xiaoping ; Zhang, Zhi Qiang ; Tobery, Timothy W. ; Davies, Mary Ellen ; McDermott, Adrian B. ; O'Connor, David H. ; Fridman, Arthur ; Bagchi, Ansu ; Tussey, Lynda G. ; Bett, Andrew J. ; Finnefrock, Adam C. ; Fu, Tong Ming ; Tang, Aimin ; Wilson, Keith A. ; Chen, Minchun ; Perry, Helen C. ; Heidecker, Gwendolyn J. ; Freed, Daniel C. ; Carella, Anthony ; Punt, Kara S. ; Sykes, Kara J. ; Huang, Lingyi ; Ausensi, Virginia I. ; Bachinsky, Margaret ; Sadasivan-Nair, Usha ; Watkins, David ; Emini, Emilio A. ; Shiver, John W. / Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. In: Journal of Virology. 2005 ; Vol. 79, No. 24. pp. 15547-15555.
@article{4d4563f78e9c42f6bf933f1f9396652e,
title = "Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag",
abstract = "The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SFVmac239 challenge. Cohorts of either Mamu-A*01(+) or Mamu-A*01(-) macaques were immunized with a DNA prime-Ad5 boost regimen; for comparison, a third cohort consisting of Mamu-A*01(+) monkeys was immunized using the Ad5 vector alone for both prime and boost. All animals, along with unvaccinated control cohorts of Mamu-A*01(+) and Mamu-A*01(-) macaques, were challenged intrarectally with SFVmac239. Viral loads were measured in both peripheral and lymphoid compartments. Only the DNA prime-Ad5-boosted Mamu-A*01(+) cohort exhibited a notable reduction in peak plasma viral load (sevenfold) as well as in early set-point viral burdens in both plasma and lymphoid tissues (10-fold) relative to those observed in the control monkeys sharing the same Mamu-A*01 allele. The degree of control in each animal correlated with the levels of Gag-specific immunity before virus challenge. However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed.",
author = "Casimiro, {Danilo R.} and Fubao Wang and Schleif, {William A.} and Xiaoping Liang and Zhang, {Zhi Qiang} and Tobery, {Timothy W.} and Davies, {Mary Ellen} and McDermott, {Adrian B.} and O'Connor, {David H.} and Arthur Fridman and Ansu Bagchi and Tussey, {Lynda G.} and Bett, {Andrew J.} and Finnefrock, {Adam C.} and Fu, {Tong Ming} and Aimin Tang and Wilson, {Keith A.} and Minchun Chen and Perry, {Helen C.} and Heidecker, {Gwendolyn J.} and Freed, {Daniel C.} and Anthony Carella and Punt, {Kara S.} and Sykes, {Kara J.} and Lingyi Huang and Ausensi, {Virginia I.} and Margaret Bachinsky and Usha Sadasivan-Nair and David Watkins and Emini, {Emilio A.} and Shiver, {John W.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1128/JVI.79.24.15547-15555.2005",
language = "English",
volume = "79",
pages = "15547--15555",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "24",

}

TY - JOUR

T1 - Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag

AU - Casimiro, Danilo R.

AU - Wang, Fubao

AU - Schleif, William A.

AU - Liang, Xiaoping

AU - Zhang, Zhi Qiang

AU - Tobery, Timothy W.

AU - Davies, Mary Ellen

AU - McDermott, Adrian B.

AU - O'Connor, David H.

AU - Fridman, Arthur

AU - Bagchi, Ansu

AU - Tussey, Lynda G.

AU - Bett, Andrew J.

AU - Finnefrock, Adam C.

AU - Fu, Tong Ming

AU - Tang, Aimin

AU - Wilson, Keith A.

AU - Chen, Minchun

AU - Perry, Helen C.

AU - Heidecker, Gwendolyn J.

AU - Freed, Daniel C.

AU - Carella, Anthony

AU - Punt, Kara S.

AU - Sykes, Kara J.

AU - Huang, Lingyi

AU - Ausensi, Virginia I.

AU - Bachinsky, Margaret

AU - Sadasivan-Nair, Usha

AU - Watkins, David

AU - Emini, Emilio A.

AU - Shiver, John W.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SFVmac239 challenge. Cohorts of either Mamu-A*01(+) or Mamu-A*01(-) macaques were immunized with a DNA prime-Ad5 boost regimen; for comparison, a third cohort consisting of Mamu-A*01(+) monkeys was immunized using the Ad5 vector alone for both prime and boost. All animals, along with unvaccinated control cohorts of Mamu-A*01(+) and Mamu-A*01(-) macaques, were challenged intrarectally with SFVmac239. Viral loads were measured in both peripheral and lymphoid compartments. Only the DNA prime-Ad5-boosted Mamu-A*01(+) cohort exhibited a notable reduction in peak plasma viral load (sevenfold) as well as in early set-point viral burdens in both plasma and lymphoid tissues (10-fold) relative to those observed in the control monkeys sharing the same Mamu-A*01 allele. The degree of control in each animal correlated with the levels of Gag-specific immunity before virus challenge. However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed.

AB - The prophylactic efficacy of DNA and replication-incompetent adenovirus serotype 5 (Ad5) vaccine vectors expressing simian immunodeficiency virus (SIV) Gag was examined in rhesus macaques using an SFVmac239 challenge. Cohorts of either Mamu-A*01(+) or Mamu-A*01(-) macaques were immunized with a DNA prime-Ad5 boost regimen; for comparison, a third cohort consisting of Mamu-A*01(+) monkeys was immunized using the Ad5 vector alone for both prime and boost. All animals, along with unvaccinated control cohorts of Mamu-A*01(+) and Mamu-A*01(-) macaques, were challenged intrarectally with SFVmac239. Viral loads were measured in both peripheral and lymphoid compartments. Only the DNA prime-Ad5-boosted Mamu-A*01(+) cohort exhibited a notable reduction in peak plasma viral load (sevenfold) as well as in early set-point viral burdens in both plasma and lymphoid tissues (10-fold) relative to those observed in the control monkeys sharing the same Mamu-A*01 allele. The degree of control in each animal correlated with the levels of Gag-specific immunity before virus challenge. However, virus control was short-lived, and indications of viral escape were evident as early as 6 months postinfection. The implications of these results in vaccine design and clinical testing are discussed.

UR - http://www.scopus.com/inward/record.url?scp=29244455769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244455769&partnerID=8YFLogxK

U2 - 10.1128/JVI.79.24.15547-15555.2005

DO - 10.1128/JVI.79.24.15547-15555.2005

M3 - Article

VL - 79

SP - 15547

EP - 15555

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 24

ER -